International Clinical Trials in Obstetrics/Gynecology

Albania

• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Tirana; Research Site:
  
  

Algeria

• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Alger; Research Site:
  
  

Argentina

• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Corporacion Medica De General San Martin
  
  
• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Hospital Britanico De Buenos Aires
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Cordoba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mar Del Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mendoza; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  San Martin; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Santa Fe; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Córdoba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Mar Del Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Tucuman; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Chaco-Resistencia; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Córdoba; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mendoza; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Buenos Aires ; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Buenos Aires ; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Santa Fe; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Buenos Aires ; Research Site:
  
  

Australia

• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Liverpool; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Lismore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Nambour; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Port Macquarie; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Darlinghurst; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  East Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Frankston; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Gosford; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Lismore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Maroochydore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Richmond; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wodonga; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Frankston; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Heidelberg; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Hobart; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Malvern; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Wodonga; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Southport; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Patients With Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Fitzroy; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Heidelberg; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Malvern; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Melbourne; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Nambour; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Parkville; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Port Macquarie; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Waratah; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Frankston; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Heidelberg; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Liverpool; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Toowoomba; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wodonga; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  St. Leonards; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  Sydney; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Darlinghurst; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Melbourne; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Nedlands; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  St. Leonards; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Sydney; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Adelaide; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Parkville; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Perth; Research Site:
  
  
• Urinary Incontinence: A research study for patients with symptoms of overactive bladder.
  Adelaide, SA; Royal Adelaide Hospital
  
  

Austria

• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Bludesch; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Bregenz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Dornbirn; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Hall In Tirol; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Klagenfurt; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Krems; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Kufstein; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Linz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Ried-Innkreis; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St Pölten; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St Veit an der Glan; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Steyr; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Villach; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wiener Neustadt; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Zams; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Klagenfurt; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Bludesch; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wiener Neustadt; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wolfsberg; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Bludesch; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Graz; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Innsbruck; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Klagenfurt; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Linz; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  St Veit an der Glan; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Villach; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wels; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wiener Neustadt; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Bregenz; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Graz; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Innsbruck; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Linz; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Salzburg; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Vöcklabruck; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Wien; Research Site:
  
  

Belgium

• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Bruxelles; Jules Bordet Institut, Department of Oncology
  
  
• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Wilrijk; Sint-Augustinusziekenhuis, Oncologisch Centrum
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Wilrijk; Research Site:
  
  
• Breast Cancer: A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
  Bruxelles; Cliniques Universitaires Saint-Luc
  
  
• Breast Cancer: A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
  Bruxelles; Institut Jules Bordet
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Brasschaat; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Charleroi; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With c-erbB2-Positive Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Patients With Metastatic Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Baudour; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Bruxelles; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Hasselt; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sint-Niklaas; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wilrijk; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Antwerpen; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Baudour; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Charleroi; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Kortrijk; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Leuven; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Liege; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Oostende; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Verviers; Research Site:
  
  
• Breast Cancer: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
  Bruxelles; Cliniques Universitaires Saint-Luc
  
  
• Breast Cancer: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
  Bruxelles; Institut Jules Bordet
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Bruxelles; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Leuven; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Wilrijk; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Gent; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Leuven; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
  Merksem; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  Bruxelles; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Aalst; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Antwerpen; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Aye; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Braine L'Alleud; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Brugge; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Bruxelles; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Charleroi; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Dinant; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Ekeren; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Genk; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Gent; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Godinne; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Hasselt; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Jambes; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Knokke; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Kortrijk; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  La Louviere; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Mechelen; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Merksem; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Mons; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Oostende; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Roeselare; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Sijsele; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Tournai; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Turnhout; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Waremme; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Wilrijk; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Bruxelles; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Merksem; Research Site:
  
  

Bosnia and Herzegovina

• Breast Cancer: A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
  Mostar; Research Site:
  
  
• Breast Cancer: A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
  Sarajevo; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sarajevo; Research Site:
  
  
• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Banja Luka; Research Site:
  
  
• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Sarajevo; Research Site:
  
  
• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Tuzla; Research Site:
  
  

Brazil

• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Barretos; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Florianopolis; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Barretos; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Belo Horizonte; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Florianopolis; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Belo Horizonte; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Campinas; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Curitiba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Fortaleza; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Niteroi; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Piracicaba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Recife; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Ribeirão Preto; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Salvador; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Santos; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sorocaba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Vitoria; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Caxias do Sul; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Fortaleza; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Ribeirão Preto; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Salvador; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Santo Andre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Santos; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sorocaba; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Itajaí; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Santo Andre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Sorocaba; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Belo Horizonte; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Campinas; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Caxias do Sul; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Curitiba; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Florianopolis; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Fortaleza; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Itajaí; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Lajeado; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Natal; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Niteroi; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Petrópolis; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Ribeirão Preto; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Salvador; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Santo Andre; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Santos; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Sorocaba; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Taguatinga; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Teresina; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Santo Andre; Research Site:
  
  
• Breast Cancer: This is a multi-national, double-blind, placebo controlled study in patients with locally advanced or metastatic breast cancer.
  Various Cities; SOLTI (Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos)
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Brasilia; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Curitiba; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Goiania; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Porto Alegre; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Rio De Janeiro; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Sao Paulo; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Vitoria; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Brasilia; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Sao Paulo; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Vitoria; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
  Sao Paulo; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Campinas; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Curitiba; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Porto Alegre; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Sao Paulo; Research Site:
  
  

Buenos Aires

• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Sanatorio Güemes
  
  

Bulgaria

• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Plovdiv; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sofia; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Varna; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Veliko Tarnovo; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
  Plovdiv; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
  Sofia; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
  Veliko Tarnovo; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Plovdiv; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Sofia; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Stara Zagora; Research Site:
  
  

Canada

• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Greenfield Park, QC; Hopital Charles Lemoyne
  
  
• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Greenfield Park, Quebec; Research Site
  
  
• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Montreal, QC; McGill University Health Center - Montreal General Hospital
  
  
• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Montreal, Quebec; Research Site
  
  
• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Toronto, ON; Toronto-Sunnybrook Regional Cancer Centre
  
  
• Breast Cancer: A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
  Toronto, Ontario; Research Site
  
  
• Breast Cancer: A PK-Loading Study of q3w Herceptin (Trastuzumab) Monotherapy in Women With HER2 Positive Metastatic Breast Cancer.
  Greenfield Park, QC; Research Site:
  
  
• Breast Cancer: A PK-Loading Study of q3w Herceptin (Trastuzumab) Monotherapy in Women With HER2 Positive Metastatic Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A PK-Loading Study of q3w Herceptin (Trastuzumab) Monotherapy in Women With HER2 Positive Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Halifax, NS; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sudbury, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Halifax, NS; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Sudbury, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Barrie, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Brampton, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Mississauga, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Newmarket, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Quebec City, QC; Research Center
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Regina, SK; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sault Ste Marie, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Scarborough, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St. Catharines, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Surrey, BC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Windsor, ON; Research Site:
  
  
• Breast Cancer: A Study of Epothilone D in Patients With Metastatic Breast Cancer
  Laval, QC; Research Site:
  
  
• Breast Cancer: A Study of Epothilone D in Patients With Metastatic Breast Cancer
  Moncton, NB; Research Site:
  
  
• Breast Cancer: A Study of Epothilone D in Patients With Metastatic Breast Cancer
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Epothilone D in Patients With Metastatic Breast Cancer
  Windsor, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Brampton, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Newmarket, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  North Vancouver, BC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Thunder Bay, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Brampton, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Greenfield Park, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Oshawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Kingston, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Moncton, NB; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  London, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Greenfield Park, QC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Halifax, NS; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Kingston, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  London, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Moncton, NB; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Oshawa, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Saskatoon, SK; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  St John'S; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sudbury, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Surrey, BC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Weston, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Windsor, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Brampton, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Calgary, AB; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Newmarket, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  North Vancouver, BC; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sault Ste Marie, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  St John'S; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Weston, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Windsor, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Charlottetown, PE; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Kelowna, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Mississauga, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Regina, SK; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Saskatoon, SK; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Sault Ste Marie, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  St. Catharines, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Surrey, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Victoria, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Windsor, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Greenfield Park, PQ; Hopital Charles LeMoyne
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Montreal, PQ; Sir Mortimer B. Davis - Jewish General Hospital
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Quebec City, PQ; Hopital du St. Sacrement
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Toronto, ON; Toronto Sunnybrook Regional Cancer Center
  
  
• Breast Cancer: Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
  Edmonton, AB; Research Center
  
  
• Breast Cancer: Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
  Toronto, Ontario; Research Center
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Calgary, AB; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Kelowna, BC; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Surrey, BC; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Vancouver, BC; Research Site:
  
  
• Ovarian Cancer: National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
  Edmonton; Cross Cancer Institute
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Laval, QC; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Montreal, QC; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Saskatoon, SK; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Toronto, ON; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Calgary, AB; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Quebec City, QC; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Toronto, ON; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Vancouver, BC; Research Site:
  
  
• Urinary Incontinence: A research study for patients with symptoms of overactive bladder.
  Victoria, BC; Dr. Steinhoff Clinical Research
  
  
• Urinary Incontinence: A research study for patients with symptoms of overactive bladder.
  Victoria, BC; Can-Med Clinical Research Inc.
  
  

Chile

• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Santiago; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
  Santiago; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
  Vina Del Mar; Research Site:
  
  

China

• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Beijing; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women